Please assess the completion status of the following clinical trial:

Trial Title: Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. High-risk who meet one of the following descriptions: 1). Poorly differentiated carcinoma (including neuroendocrine tumors); 2). Vascular invasion; 3). Tumor diameter≥4cm 5). Visceral pleura involvement.~2. Patients with pathology confirmed Ib stage NSCLC~3. Patients with deletion of exon 19 or mutation of L858R at exon 21 in EGFR gene~4. ECOG score of 0-1~5. Life expectancy over 12 weeks~6. Absolute neutrophil count (ANC) \>= 1.75 x 109 / L, platelet \>= 100 x 109 / L, hemoglobin is more than or equal to 9 g / dl~7. Total bilirubin \<= the normal value of 1.5 times the upper limit of normal (ULN); liver metastases, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \<= 2.5 times of upper limit of normal (ULN)~8. Serum creatinine \<=1.25 times of the upper limit of normal value, creatinine clearance rate \> 60 or ml/min~9. received the informed consent from patient or his/her legal representative~Exclusion Criteria:~1. Patients who was serious allergy to any of the ingredients of drugs used in this study~2. Patients who unable to comply with the study plan or research program;~3. Patients with severe systemic disease that the researchers judged will be unable to complete the study;~4. Patients have severe heart disease, such as myocardial infarction within 6 months;~5. Patients have interstitial pneumonia;~6. Patients who were confirmed to be positive pathology for cutting edge;~7. The preoperative chest CT showed nodules \>= 50%, and showed ground glass opacity;~8. Patients received wedge resection;~9. Patients used HER2 pathways involved drugs such as erlotinib, gefitinib, cetuximab rituximab, trastuzumab)~10. Patients who have received chemotherapy or systemic antitumor therapy (such as monoclonal antibody therapy);~11. Patients received radiotherapy;~12. Having other malignant tumors in the last 5 years, but not including who has been cured through surgery and survived 5 year of disease-free;~13. Any unstable systemic diseases (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction, serious arrhythmias, liver, kidney or metabolic diseases within six months).~14. Patients who do not get effective treatment of inflammation, eye infections or predisposing factors;~15. Physical examination or laboratory findings evidence reasonable doubt who is ill or use of related drugs could affect the study;~16. Patients with serious active infections;~17. Patients with T790M mutations at 20 exon;~18. Woman who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Gefitinib (Type: None): Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
- Non-specific treatment (Type: None): Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy